Newsroom
Advanced Search
  • Jan 7, 2020

    Salt Lake City, Utah – January 7, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of...

  • Jan 2, 2020
    CoSara tests for tuberculosis, malaria, hepatitis B, hepatitis C, and human papillomavirus recently granted regulatory approval by CDSCO to formally launch at India Diagnostic Expo

    Salt Lake City, Utah – January 2, 2020 – Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of...

  • Dec 11, 2019

    Salt Lake City, Utah – December 11, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), was recently featured in an article on genomeweb.com titled “Co-Diagnostics Continues Global Expansion With...

  • Dec 10, 2019
    Vector Smart™ NAM-e multiplex PCR test to provide proactive defense against mosquito populations carrying the deadly eastern equine encephalitis virus

    Salt Lake City, Utah – December 10, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...

  • Dec 3, 2019
    CoSara Saragene™ tests for tuberculosis, malaria, hepatitis B, hepatitis C, and human papillomavirus now available for sale and distribution as in vitro diagnostics

    Salt Lake City, Utah – December 3, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...

Show 5102550100 per page